PIK3CA and breast carcinoma: Further, in a study published by Tury and colleagues, the COX-2-selective inhibitor celecoxib was effective against PIK3CA-mutated patient-derived breast cancer xenografts, but not against PIK3CA-wildtype xenografts [197].